KAS
ANIP icon

Kemnay Advisory Services’s ANI Pharmaceuticals ANIP Stock Holding History

Kemnay Advisory Services’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-606
Closed -$47.8K – 1200
2025
Q4 		$47.8K Buy
+606
New +$52.5K 0.01% 334

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Kemnay Advisory Services's ANIP Position: Q1 2026 in Review

Kemnay Advisory Services sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 606 shares — an estimated $47.8K sold.

Kemnay Advisory Services first reported a position in ANIP in Q4 2025 and held it in 1 quarter. The position peaked at $47.8K in Q4 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Kemnay Advisory Services reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 606 ANI Pharmaceuticals shares in Q1 2026, an estimated $47.8K.
  • Kemnay Advisory Services first reported a position in ANI Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Kemnay Advisory Services's ANI Pharmaceuticals position peaked at $47.8K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Kemnay Advisory Services's 13F filing for Q1 2026, filed 15 May 2026.